Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion

News summary

Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared again.